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Abstract
Background: A Polypill is proposed for the primary prevention of cardiovascular disease in people judged to be at risk on
account of their age alone. Its efficacy in reducing cholesterol and blood pressure is uncertain.
Methods: We conducted a randomized double-blind placebo-controlled crossover trial of a Polypill among individuals aged
50+ without a history of cardiovascular disease and compared the reductions with those predicted from published
estimates of the effects of the individual drugs. Participants took the Polypill (amlodipine 2.5 mg, losartan 25 mg,
hydrochlorothiazide 12.5 mg and simvastatin 40 mg) each evening for 12 weeks and a placebo each evening for 12 weeks
in random sequence. The mean within-person differences in blood pressure and low density lipoprotein (LDL) cholesterol at
the end of each 12 week period were determined.
Results: 84 out of 86 participants completed both treatment periods. The mean systolic blood pressure was reduced by
17.9 mmHg (95% CI, 15.7–20.1) on the Polypill, diastolic blood pressure by 9.8 mmHg (8.1–11.5), and LDL cholesterol by
1.4 mmol/L (1.2–1.6), reductions of 12%, 11%, and 39% respectively. The results were almost identical to those predicted;
18.4 mmHg, 9.7 mmHg, and 1.4 mmol/L respectively.
Conclusion: The Polypill resulted in the predicted reductions in blood pressure and LDL cholesterol. Long term reductions
of this magnitude would have a substantial effect in preventing heart attacks and strokes.
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Introduction
A combination pill for the prevention of cardiovascular
disease was first described in 2000 [1], and called a Polypill. [2]
Several Polypills have been made and assessed with respect to
cholesterol and blood pressure reductions in people selected, on
the basis of multiple risk factor measurement, to be at increased
risk of cardiovascular disease. These trials[3–6] showed signif-
icant reductions in blood pressure and cholesterol, but estimates
of the magnitude of the effects varied, and were lower than
those expected from previous research. [2,7,8] There are several
reasons for this. [9] The four previous Polypill trials underes-
timated efficacy because of poor adherence to treatment in the
treated group or unscheduled treatment in the control group. In
two trials the proportion of participants who stopped taking
their treatment was 16% [3] and 23% [4]; in a third trial 30–
35% were reported as not having taken their allocated pills [5];
in the fourth trial [6] more than 68% of controls took the
Polypill components and the authors acknowledged that the trial
could not estimate the risk factor reduction on the Polypill used.
All four previous trials used a parallel group design in which
participants who either stopped taking their treatment or took
additional treatment needed to be included in an intention-to-
treat analysis to avoid selection bias but at the cost of
underestimating efficacy.
The uncertainty over the true efficacy prompted us to
conduct a trial of a Polypill, intended for the primary
prevention of cardiovascular disease in people selected only on
the basis of age (50 years and over). This Polypill consisted of
three blood pressure lowering agents (amlodipine 2.5 mg,
losartan 25 mg and hydrochlorothiazide 12.5 mg), all at half
standard doses and simvastatin 40 mg (standard dose). We used
a randomized crossover design to avoid the under-estimation of
the risk factor reduction that may have occurred in the previous
trials.[3–6] The aim of the study was to quantify the effect of
this Polypill on blood pressure and serum LDL cholesterol and
to compare the observed effects with those previously predicted.
[2,7,8].
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Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
Ethics Committee approval was obtained from the North
London Research Ethics Committee 1 and a clinical trials
authorization obtained from the Medicines and Healthcare
products Regulatory Agency. The trial is registered on the
ISRCTN Register (ISRCTN36672232).
Trial Design
We conducted a randomized placebo-controlled double-blind
crossover trial of the Polypill described above, manufactured for
the study group by Cipla, India. To help achieve high adherence
during the trial, participants were recruited from individuals
already taking simvastatin and blood pressure lowering drugs as
part of a cardiovascular disease prevention programme. [10]
Individuals were eligible to participate in the programme and,
therefore, also the trial if they were aged 50 or over without an
upper age limit, had no self reported history of cardiovascular
disease, and were not taking drugs contraindicated with the
Polypill components. Participants were not selected based on
blood pressure or cholesterol measurements. Recruitment to the
trial was limited to people who lived in London or could easily
travel to London, where the trial was conducted. Written consent
was obtained from the participants.
Figure 1 is a flow chart of the trial. Trial participants took the
Polypill (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothi-
azide 12.5 mg) for 12 weeks, and an identical placebo for
12 weeks, the sequence being allocated at random. Neither the
participants nor the investigators knew the sequence (ie. ‘‘double-
blind’’). Study treatment was taken once a day in the evening
because of the greater efficacy of simvastatin when taken in the
evening than in the morning. Existing blood pressure and
cholesterol lowering treatments were discontinued at randomisa-
tion and no participant received additional blood pressure or
cholesterol lowering treatment during the study. The randomiza-
tion sequence was generated in advance by a computer random
number generator, in blocks of 4. Date of birth, height, weight,
and sex were recorded at randomization.
Blood pressure and lipid measurements were taken at the end of
each 12 week period (usually between 10am and 2pm). Twelve
weeks on the placebo was judged sufficient time for the drugs in
the Polypill to have ‘‘washed out’’, avoiding any carry-over effects
because it has been shown that LDL cholesterol returns to pre-
treatment levels within 4 weeks of stopping statin treatment [11]
and it is standard practice to allow the same time period for blood
pressure lowering treatment. [12] Blood pressure was measured,
seated, after five minutes rest, with an automated sphygmoma-
nometer (Omron, model 705IT, Kyoto, Japan); the average of two
measurements, taken from the same arm, five minutes apart, was
used. Venous blood samples were refrigerated, spun within
2 hours of collection and analysed within 6 hours in the Wolfson
Institute of Preventive Medicine, London. Direct quantitative
determinations of serum lipids were performed, using a Beckman
Coulter Synchron analyser, to avoid the need for fasting.
The trial was not designed to assess side-effects of the Polypill
but, as a safety measure, at the end of each 12-week treatment
period participants completed a questionnaire on recognized side-
effects of the component medications (cough, muscle ache or pain,
ankle swelling, flushing, rash, tongue and lip swelling) and
answered an open question on any other symptoms that might
be attributable to the study medication. Adherence was assessed by
a study investigator counting the remaining pills in each
participant’s blister pack at the end of each treatment period. At
the end of the trial participants continued on the Polypill.
Statistical Methods
The main statistical analysis was a comparison of the mean
within-person absolute and relative differences in systolic and
diastolic blood pressure and the five lipid measurements (LDL
cholesterol, HDL cholesterol, total cholesterol, triglyceride and
ApoB) after taking the polypill compared with after taking the
placebo. Paired t-tests were used to calculate statistical signifi-
cance. Statistical power calculations indicated that 80 participants
would provide a greater than 90% power with an alpha level of
,0.05 (two tailed) if the LDL cholesterol reduction was at least
1.3 mmol/L (standard deviation 1 mmol/L) and diastolic blood
pressure reduction was at least 9 mmHg (standard deviation
6 mmol/L).
The observed effects of the Polypill were compared with those
expected frommeta-analyses of the individual components. [1,2,7,8]
The cholesterol meta-analysis yielded the estimates that 40 mg
simvastatin lowered LDL cholesterol by 37%, a relative reduction
that was independent of the pre-treatment LDL cholesterol value,
while the absolute cholesterol reduction (in mmol/L) increased with
pre-treatment level. The blood pressure meta-analysis showed that
the three blood pressure lowering drugs used in our Polypill would
lower blood pressure by 19.9 mmHg systolic and 10.7 diastolic from
pre-treatment values of 150 mmHg, and 90 mmHg, respectively,
and published regression equations [13] were used to predict the
reductions from lowerpre-treatment bloodpressure levels. Statistical
analyses were performed using Stata (version 10, StataCorp LP,
College Station, Texas).
Results
Between December 2010 and March 2011, 116 individuals
were invited to join the trial, 86 participants accepted and 84
completed both treatment periods (see figure 1). Participant
characteristics are shown in table 1 including pre-trial medicines
discontinued and blood pressure and lipid measurements at the
end of the placebo period. Two participants did not complete the
trial (both stopped during the placebo period), one because she
wanted to stop treatment and the other because she wanted to be
sure she received it. The sequence of treatment periods was
balanced (43 Polypill first, and 43 placebo first). Table 2 shows the
mean absolute and relative differences in blood pressure and lipid
measurements while taking the Polypill compared with the
placebo. Compared with placebo, mean systolic blood pressure
reduced by 17.9 mmHg (12%) and diastolic blood pressure by
9.8 mmHg (11%) on the Polypill. LDL cholesterol reduced by
1.4 mmol/L (39%). In addition, apoB, total cholesterol, and
triglyceride (even though non-fasting) levels were significantly
reduced but HDL was not.
Figure 2 shows the observed blood pressure and LDL cholesterol
reductions compared with those expected from meta-analyses of
randomized trials of the individual classes of Polypill components
[1,2,7,8], allowing for the lower baseline blood pressure and LDL
cholesterol in our trial participants (systolic blood pressure
143 mmHg compared with 150 mmHg, diastolic blood pressure
86 mmHg compared with 90 mmHg, and LDL cholesterol
3.7 mmol/L compared with 4.8 mmol/L). Figure 2 shows that the
trial results using the Polypill are close to those expected.
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Pill counts at the end of each treatment period indicated that
98% of participants (80/82, two forgot to bring their blister packs)
took more than 85% of their allocated pills (same numbers on
Polypill and placebo). Twenty four out of 84 participants reported
one or more symptoms on the Polypill, compared with 11 on the
placebo (p = 0.01) but none of these participants considered them
troublesome enough to stop treatment. Muscle ache was more
common on the Polypill than on placebo (9 v 1). No participant
had a serious adverse event.
Figure 1. Flow chart of crossover trial.
doi:10.1371/journal.pone.0041297.g001
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Discussion
This is the first randomized trial of a Polypill offered to people
on the basis of age alone; participants accepted that there was no
need to know their blood pressure or their cholesterol level
measurements which add little to age in predicting ischaemic heart
disease events and strokes.[14] The results show substantial
reductions in blood pressure and LDL cholesterol that were
remarkably similar to those previously predicted.[1,2,7,8] The
results are likely to be more accurate than those from the other
Polypill trials [3–6] because while the other trials used a parallel
group design, we used a crossover design that has greater statistical
power and avoids the dilution of the estimate of effect due to
participants who did not take their allocated treatments being
included in the results as part of the intention-to-treat analysis.
Our results show that the original predictions were accurate and
not overestimated as has been suggested.[3,15].
Our trial has important strengths. The crossover design,with each
participant being his or her own control, has the advantage of
providingmore precise and accurate estimates of blood pressure and
cholesterol lowering effects withmany fewer participants thanwould
be needed using a parallel group design to achieve the same level of
precision and, unlike a parallel group trial, participants who
discontinue treatment can be excluded without introducing bias
(two participants in our trial). A parallel group trial design would
require four to five times asmanyparticipants to yield results with the
same level of precision assuming 100% adherence to the allocated
treatment,which is rarelyachievable inpracticewithsuchadesign. In
our trial we achieved high adherence by recruiting participants
already taking Polypill components. However, achieving a high
Table 1. Characteristics of the trial participants including medications discontinued at randomisation and blood pressure and lipid
measurements at the end of the placebo period.
Characteristic
Age: mean (range) 59 (51–77)
Sex
Number of men (%) 64 (74)
Number of women (%) 22 (26)
Smoking
Number of Smokers 8 (9)
Body Mass Index (kg/m2): mean 6150 2864
Pre-trial prescribed medicines discontinued at randomisation: number (%)
simvastatin (40mg/d) 86 (100)
bendrofluazide (1.25mg/d) 86 (100)
amlodipine (2.5mg/d) 86 (100)
lisinopril (5mg/d) 69 (80)
losartan (25mg/d) 17 (20)
Blood Pressure at end of placebo period: mean 61SD
Systolic (mmHg) 143616
Diastolic (mmHg) 86610
Lipid measurements at end of placebo period: mean 61SD
Total cholesterol (mmol/L*) 5.961.0
LDL cholesterol (mmol.L*) 3.760.9
HDL cholesterol (mmol/L*) 1.460.4
Triglycerides (mmol/L*) 1.861.0
ApoB (g/L) 1.260.2
*Conversion to mg/dL: multiply by 38.67 for cholesterol and by 88.57 for triglyceride.
doi:10.1371/journal.pone.0041297.t001
Table 2. Absolute and relative difference in blood pressure
(BP) and lipid measurements in 84 participants while taking
the Polypill, compared with the placebo.
Absolute difference* Relative difference**
Mean 95% CI P Mean 95% CI P
Systolic
BP
(mmHg)
217.9 220.1,215.7 ,0.001 12% 14%,11% ,0.001
Diastolic
BP
(mmHg)
29.8 211.5,28.1 ,0.001 11% 13%,9% ,0.001
LDL
cholesterol
(mmol/l)
21.4 21.6,21.2 ,0.001 39% 43%,34% ,0.001
ApoB
(g/L)
20.4 20.4,20.3 ,0.001 30% 34%,26% ,0.001
Cholesterol
(mmol/l)
21.6 21.8,21.3 ,0.001 27% 30%,23% ,0.001
Triglycerides
(mmol/l)
20.4 20.6,20.2 0.001 23% 33%,13% 0.001
HDL
cholesterol
(mmol/l)
0.03 20.03,0.08 0.34 22% 2%,26% 0.34
*Polypill minus placebo.
**(Placebo minus Polypill)/placebo for each participant. Mean percentage
differences are not precisely derivable from the absolute differences because of
rounding and averaging within-person differences.
doi:10.1371/journal.pone.0041297.t002
Randomized Polypill Crossover Trial
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e41297
adherence to treatment in this way means that the trial also has two
limitations. First, the observed adherence rate cannot be used to
estimate adherence in the general population. Second, the results on
tolerability cannot beused to estimate the prevalence of side effects in
peoplewhohavenotpreviously takenPolypill components. In spiteof
this, the results revealed an increased prevalence of muscle ache
associated with statin use that was not severe enough to stop
treatment. Previous work has estimated side effect rates. In one study
7%of individuals didnot tolerate oneormoreof thedrugsused inour
Polypill [10] (1.25 mg bendrofluazide used instead of 12.5 mg
hydrochlorothiazide); about half of this 7% needed modification of
the regimen (4%) and half (3%) stopped treatment.
The Polypill we used excluded folic acid and aspirin. Folic acid
was excluded because obtaining regulatory approval for a Polypill
that included folic acid was judged to be uncertain given the lack
of proven efficacy in clinical trials. Aspirin was excluded because
the risk of bleeding in people without existing cardiovascular
disease might be unacceptable in relation to the expected benefit
although recent work indicating a protective effect against cancer
may alter this assessment.[16,17].
Given the composition of the Polypill we used, and the observed
LDL cholesterol and blood pressure reductions, the predicted
effect in reducing ischaemic heart disease events is 72% and in
reducing stroke is 64% based on evidence of the quantitative
relationship between the two risk factors and risk.[2,13,18–22]
This Polypill, designed principally for primary prevention,
therefore has considerable potential for the prevention of
cardiovascular disease.
Supporting Information
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Trial Protocol.
(DOC)
Acknowledgments
We thank the following individuals who agreed to take part in the trial: Mark
Allen, Fred Allsworth, Jeff Aronson, Bev Astley, JohnAttree, Stuart Attridge,
John Bance, John Baxendale, Lesley Baxendale, Edwina Blow, Alan Brown,
David Brown, Janet Brown, Charles Cachia, Johann Carinus, Geoff Carr,
John Carter, William Chubb, Stephen Clark, Michael Connors, Clifford
Cottis, Richard Croxson, Jerry Cutter, Jack Cuzick, Peter Emery, Margaret
Eynon, Melanie Faux, Robert Gibbens, Maureen Gilbert, Peter Hajek,
Stephen Harmsworth, Helen Harvey, Tony Head, John Hicks, Martin
Hinkley, Guy Hitchcock, Ron Hodgson, Tony Hudson, Barrie Jennings,
Anna Keeling, David Keeling, Mary Keeling, Colin Kennedy, Ray King,
SandraKing,DuncanLocke, PeterMace, IanManners, JohnMcElroy, John
Meehan, David Meyer, John Norton, Max Parkin, Sara Parkin, John
Rainford, IanRodgers, PeterRogers,Douglas Scales,KevinSchembri, Janet
Showler, Joan Smith, Richard Smith, Janet Stewart, David Sylvester, David
Taylor, GrahamTelford, Andrea Thompson, Ian Thompson, Laurie Todd,
Nancy Wald, David Wallis, Geoff Westwood, Janice Westwood, Beatrice
Weydert, ShelaghWhall, RobertWhiley, LizWright,RaymondWright, and
eight individuals who wished to remain anonymous. We also thank Angela
Godoy for helping to administer the trial, Lynne George for supervising the
laboratory analyses, and Malcolm Law for his helpful critical comments. All
authorshadaccess to thedataand take responsibility for their integrityand the
accuracy of the data analysis.
Author Contributions
Conceived and designed the experiments: DSW JKM NJW. Analyzed the
data: DSW JKM NJW. Wrote the paper: DSW JKM NJW.Figure 2. Observed and expected reduction in blood pressure
and LDL cholesterol on the Polypill.
doi:10.1371/journal.pone.0041297.g002
Randomized Polypill Crossover Trial
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41297
References
1. Wald NJ, Law MR (2000) Formulation for the Prevention of Cardiovascular
Disease. UK Patents GB008791 and GB0100548.
2. Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more
than 80%. BMJ 326:1419–23.
3. The Indian Polycap Study (TIPS) (2009) Effects of a polypill (Polycap) on risk
factors in middle-aged individuals without cardiovascular disease (TIPS): a phase
II, double-blind, randomised trial. Lancet 373:134151.
4. PILL Collaborative Group (2011) AN international randomised placebo-
controlled trial of a four-component combination pill (‘‘Polypill’’) in people
with raised cardiovascular risk. PlosOne doi:10.1371/journal.pone.0019857.
5. Soliman ES, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, et
al (2011) A Polypill for primary prevention of cardiovascular disease: A feasibility
study of the World Health Organization. Trials12:3.
6. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, et al (2010) A
pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose
combination therapy (‘polypill) on cardiovascular risk factors. Int J Clin Pract
64:1220–7.
7. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying the effect of statins on low
density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic
review and meta-analysis. BMJ 326: 1423–7.
8. Law MR, Wald NJ, Morris JK, Jordan RE (2003) Value of low dose
combination treatment with blood pressure lowering drugs: analysis of 354
randomised trials. BMJ 326:1427–31.
9. Wald N, Law M (2009) The Indian Polycap Study (TIPS) Lancet 374:781.
10. Wald DS, Wald NJ (2011) Implementation of a simple age-based strategy in the
prevention of cardiovascular disease: the Polypill approach. Journal of
Evaluation in Clinical Practice. doi: 10.1111/j.1365–2753.2011.01637.
11. Cilla DD, Gibson DM, Whitfield LR, Sedman AJ (1996) Pharmacodynamic
effects and pharmacokinetics of Atorvastatin after administration to normocho-
leterolemic subjects in the morning and evening. J Clin Pharmacol 36:604–9.
12. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, et al (2002) Drug effects
on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension
40:897–902.
13. Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in
the prevention of cardiovascular disease: meta-analysis of 147 randomised trials
in the context of expectations from prospective epidemiological studies. BMJ
338:b1665.
14. Wald NJ, Simmonds M, Morris JK (2011) Screening for future cardiovascular
disease using age alone compared with multiple risk factors and age. PLoS One
6(5):e18742.
15. Van Gils PF, Over EAB, Hamberg-van Reenen HH, de Wit GA, van den Berg
M, et al (2012) The polypill in the primary prevention of cardiovascular disease:
cost-effectiveness in the Dutch population. BMJ Open 2–11;1:e000363.
16. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, et al (2010) Effect
of daily aspirin on long-term risk of death due to cancer: analysis of individual
patient data from randomised trials. Lancet DOI:10.1016/S0140-6736(10)62110-
1.
17. Wald NJ, Morris JK, Law MR (2011) Aspirin in the prevention of cancer. Lancet
377:1649.
18. Law MR, Wald NJ, Morris JK, Jordan RE (2003) Value of low dose
combination treatment with blood pressure lowering drugs: analysis of 354
randomised trials. BMJ 326:1427–31.
19. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low
density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic
review and meta-analysis. BMJ 326:1423–7.
20. Prospective Studies Collaboration (2002) Age-specific relevance of usual blood
pressure to vascular mortality: a meta-analysis of individual data for one million
adults in 61 prospective studies. Lancet 360:1903–13.
21. Prospective Studies Collaboration (2007) Blood cholesterol and vascular
mortality by age, sex, and blood pressure: a meta-analysis of individual data
from 61 prospective studies with 55000 vascular deaths. Lancet 370:1829–39.
22. Cholesterol Treatment Trialists (CTT) Collaborators (2012) The effects of
lowering LDL cholesterol with statin therapy in people at low risk of vascular
disease:meta-analysis of individual data from 27 randomised trials. Lancet [Epub
ahead of print].
Randomized Polypill Crossover Trial
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41297
